Particulars (Rs. in cr) | Q3FY25 | Q3FY24 | YoY (%) | Q2FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 772.00 | 606.00 | 28.00% | 777.00 | -1.00% |
EBITDA | 187.00 | 147.00 | 27.00% | 218.00 | -14.00% |
EBITDA Margin (%) | 24.20% | 24.30% | (3) bps | 28.10% | (382) bps |
PAT | 92.00 | 77.00 | 21.00% | 121.00 | -23.00% |
EPS (Rs.) | 2.22 | 1.80 | 23.00% | 2.68 | -17.00% |
Source: Company Filings; stockaxis Research
Q3FY25 Result Highlights
KIMS delivered steady earnings growth for the quarter ended Q3FY25. Consolidated
revenues from operations rose 28% YoY to Rs.772 cr as compared to Rs.606 cr registered
in the same quarter of the corresponding fiscal. Gross margins stood at 79.05%,
contracting marginally by 22bps YoY and 94bps QoQ. Consolidated EBITDA stood at
Rs. 187cr, up 27% YoY and -14% QoQ , adjusted for one-time write-offs (8 cr-9 cr).
EBITDA margins witnessed a 382 bps QoQ contraction, which was a consequence of lower
gross margins in the comparable quarter. Consolidated Profit After Tax stood at
Rs. 92cr, up 21% YoY and -23% QoQ, impacted by higher finance costs and lower margin
profile during the quarter.
Operational Highlights
Guidance:
(i) The Telangana region, which accounts for
~65% of revenues of KIMS, is expected to continue to grow at a similar rate as seen
in Q3 (~25%), (ii) the margins are expected to inch up towards 30% post the
commencement of operations of many oncology and mother and child hospitals that
will come online in FY26, (iii) Targeting a debt to Equity of 0.8-0.9x on a sustainable
basis, (iv) Bangalore Expansion: Targeting 2,000 beds over time, with two hospitals
opening in FY25 and plans for a third by early FY26. North Bangalore may see an
additional 750 beds over 3-4 years. Kerala will also scale up to 2500-3,000 beds
over the medium to long term.
Key Milestones
Regional Performance
Maharashtra Cluster:
Telangana and AP Cluster
Kerala Cluster
Sunshine Hospitals (Telangana)
Capex and Bed Addition
Medical Tourism Revenue
Other Key Points
KIMS delivered a mixed set of numbers for the quarter ended Q3FY25. KIMS’ management pursues a strategy that is fuelled by organic expansion and acquisitions, improving the profitability of acquired businesses, and collaborative partnerships with doctors via equity stakes. KIMS is strategically positioned to bolster its market share by expanding its hospital reach to new geographies. The continuous addition of skilled doctors and advancement of technologies should further boost its vision and performance. We believe that KIMS’ doctor participation model, which focuses on multi-specialty with a well-defined philosophy, execution, and aggressive bed expansion provides a long and sustainable growth path ahead. The initiatives in the core AP-Telangana cluster and the ramp-up of new geography hospitals make it a well-diversified play in the healthcare industry. Incremental initiatives such as the addition of radiation oncology and M&C to further improve ARPOB.
We believe KIMS provides an ideal opportunity to invest in a distinctive multi-specialty hospital chain - 1) Employs a unique approach of a capex light business model in a hospital space with doctors/investor participation, 2) Cost-efficient way of running a hospital, resulting in higher margins, 3) Balanced mix of core and new market expansion, 4) Successful track record of turning around acquisitions and 5) Large scope to improve therapy mix/ARPOB with expansion in oncology, and mother & child.
KIMS Hospitals has a strong trajectory of expansion plans for the next 3 years, which should increase the total bed capacity to 6,300 in FY27, while adding over 2000 beds by FY26. Key hospitals which were acquired a couple of years back like- Sunshine Hospitals (Hyderabad), Kingsway Hospital (Nagpur), and Manavata Hospitals (Nashik) are witnessing a stronger traction and have helped accelerate growth. The recent acquisition of QNRI (Vizag) is set to aid the growth in FY25. A strong growth in operating parameters (IP/OP volume, ARPOB, ARPP) along with multiple expansion plans are likely to boost revenues for KIMS Hospitals going forward. At CMP of Rs.642.25, the stock is trading at 10.7x FY26E. We recommend HOLD rating on the stock.
Particulars (Rs. in cr) | Q3FY25 | Q3FY24 | YoY (%) | Q2FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 772.00 | 606.00 | 28.00% | 777.00 | -1.00% |
COGS | 162.00 | 126.00 | 29.00% | 156.00 | 4.00% |
Gross Profit | 611.00 | 480.00 | 27.00% | 622.00 | -2.00% |
Gross Margin (%) | 79.05% | 79.27% | (22) bps | 79.99% | (94) bps |
Employee Benefit expense | 127.50 | 104.30 | 22.00% | 119.20 | 7.00% |
Other expenses | 296.00 | 228.90 | 29.00% | 285.00 | 4.00% |
EBITDA | 187.00 | 147.00 | 27.00% | 218.00 | -14.00% |
EBITDA Margin (%) | 24.20% | 24.30% | (3) bps | 28.10% | (382) bps |
Depreciation and amortisation expenses | 44.70 | 35.40 | 26.00% | 41.00 | 9.00% |
EBIT | 143.00 | 112.00 | 28.00% | 177.00 | -20.00% |
Finance cost | 25.70 | 12.40 | 107.00% | 19.90 | 29.00% |
Other Income | 17.80 | 3.30 | 439.00% | 5.00 | 256.00% |
PBT | 135.00 | 103.00 | 31.00% | 162.00 | -17.00% |
Tax expenses | 42.10 | 25.90 | 63.00% | 41.50 | 1.00% |
PAT | 92.00 | 77.00 | 21.00% | 121.00 | -23.00% |
EPS (Rs.) | 2.22 | 1.80 | 23.00% | 2.68 | -17.00% |